Annovis Bio Inc., a Phase 3 clinical-stage biotechnology company, has announced a partnership with NeuroRPM to integrate an FDA-cleared artificial intelligence platform into its ongoing Parkinson's disease study. This collaboration aims to enhance the monitoring of symptoms such as bradykinesia, tremor, and dyskinesia through wearable and mobile technology, with the collected data serving as digital biomarkers to track disease progression more effectively.
The implementation of this AI platform will support the evaluation of buntanetap, Annovis Bio's lead drug candidate, over the 36-month trial period. By providing real-time data on patient symptoms, the technology is expected to offer deeper insights into treatment response and inform future clinical development strategies. This approach represents a significant advancement in how neurodegenerative disease trials can leverage digital tools to improve accuracy and efficiency.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43. The drug operates through a specific RNA-targeting mechanism of action, addressing underlying causes of neurodegeneration with the goal of halting disease progression and improving cognitive and motor functions in patients with Alzheimer's disease and Parkinson's disease.
The integration of NeuroRPM's AI platform into Annovis Bio's clinical study highlights the growing importance of digital health technologies in pharmaceutical research. By enabling continuous, objective measurement of symptoms that are traditionally assessed through periodic clinical visits, this approach could provide more comprehensive data on drug efficacy and patient outcomes. The partnership demonstrates how biotechnology companies are increasingly incorporating innovative monitoring solutions to enhance traditional clinical trial methodologies.
For more information about Annovis Bio, visit https://www.annovisbio.com. Additional news and updates relating to the company are available at https://ibn.fm/ANVS. BioMedWire, which distributed the announcement, provides specialized communications for the biotechnology and biomedical sectors, with more information available at https://www.BioMedWire.com.
